Because we aimed to employ synthetic lethal drug screening plus a combinatorial strategy, we assume that the drugs targeting pathways upstream of RAS, downstream of RAS or mutant RAS-dependent pathways may coordinate with each other to produce more profound actions to kill KRAS-mutant tumours by unrivalled mechanisms or signalling crosstalk. This evidence concerns the gene KRAS and neoplasm.